Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.54 |
| ▸ | CTSS | P25774 | 7/20 | 0.53 |
| ▸ | CTSK | P43235 | 7/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.51 |
| ▸ | IL2 | P60568 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 5/20 | 0.49 |
| ▸ | PPARG | P37231 | 4/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.48 |
| ▸ | ITGAV | P06756 | 1/20 | 0.48 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215510 | 1.00 | PTPN1 (0.59) | PTPN1ACEITGB3ITGA2BCTSS | |
| SCHEMBL1429759 | 1.00 | PTPN1 (0.59) | PTPN1ACEITGB3ITGA2BCTSS | |
| SCHEMBL29663847 | 1.00 | PTPN1 (0.59) | PTPN1ACEITGB3ITGA2BCTSS | |
| SCHEMBL27139552 | 0.90 | PTPN1 (0.59) | PTPN1ACEITGB3ITGA2BCTSS | |
| SCHEMBL27139554 | 0.90 | PTPN1 (0.59) | PTPN1ACEITGB3ITGA2BCTSS | |
| SCHEMBL1516520 | 0.90 | PTPN1 (0.61) | PTPN1ACEITGB3ITGA2BCTSS | |
| SCHEMBL2573377 | 0.90 | PTPN1 (0.61) | PTPN1ACEITGB3ITGA2BCTSS | |
| SCHEMBL29398351 | 0.90 | PTPN1 (0.61) | PTPN1ACEITGB3ITGA2BCTSS | |
| SCHEMBL29401347 | 0.90 | PTPN1 (0.61) | PTPN1ACEITGB3ITGA2BCTSS | |
| SCHEMBL1516519 | 0.90 | PTPN1 (0.61) | PTPN1ACEITGB3ITGA2BCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4371982-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-3583096-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20240067665-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | AVIKO RADIOPHARMACEUTICALS LLC (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240057599-A1 | METHODS FOR IMPROVING FRUIT QUALITY | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2024-02-22 | — | — | US | disclosed |
| US-11812746-B2 | Method of controlling fungal infections in plants | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION (ARO) (VOLCANI CENTER) (IL) | 2023-11-14 | — | — | US | disclosed |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| CN-110520413-B | Macrocyclic broad spectrum antibiotics | 阿奇克斯制药公司 | 2023-02-17 | — | — | CN | disclosed |
| US-11578068-B2 | Oxadiazole derivatives as Rho-Kinase Inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-02-14 | — | — | US | disclosed |
| US-11332468-B2 | Azaindole derivatives as Rho-kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-05-17 | — | — | US | disclosed |
| CN-110248939-B | Tyrosine amide derivatives as RHO-kinase inhibitors | 奇斯药制品公司 | 2022-05-17 | — | — | CN | disclosed |
| US-20090306127-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INC | 2009-12-10 | — | — | US | disclosed |
| US-20090286841-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. | 2009-11-19 | — | — | US | disclosed |
| US-7618981-B2 | to treat cellular proliferative diseases, hyperplasias, solid tumor, cardiac hypertrophy, immune disorders and inflammation; modulators of one or more mitotic kinesins; N-(2-(2-dimethylamino-acetylamino)-1-{4-[8-(1-hydroxy-ethyl)-imidazo[1,2-a]pyridin-2-yl]-benzyl}-ethyl)-3-chloro-4-isopropoxy-benzamide | CYTOKINETICS, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-7582668-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582668-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2009-09-01 | — | — | US | disclosed |
| US-7504413-B2 | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases | CYTOKINETICS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
| US-6245746-B1 | ADMINISTERING AMIDE MICROBIOCIDE ANTIBIOTIC | MICROCIDE PHARMACEUTICALS, INC. | 2001-06-12 | — | — | US | disclosed |
| US-6114310-A | THERAPY FOR MICROBIAL INFECTIONS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| WO-1999037667-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332468-B2 | Azaindole derivatives as Rho-kinase inhibitors | ROCK1, ROCK2, RHOA | PTPN1 477/4885ACE 1462/4885ITGB3 1724/4885 |
| US-11578068-B2 | Oxadiazole derivatives as Rho-Kinase Inhibitors | ROCK1, ROCK2, RHOA | PTPN1 1811/4885ACE 1658/4885ITGB3 793/4885 |
| US-20090306127-A1 | Certain Chemical Entities, Compositions and Methods | KIF5B, KIF2C, PLK1 | PTPN1 3910/4885ACE 4142/4885ITGB3 3967/4885 |
| US-20090286841-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | KIF5B, KIF2C, PLK1 | PTPN1 3710/4885ACE 4363/4885ITGB3 4000/4885 |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | PTPN1 1224/4885ACE 170/4885ITGB3 4676/4885 |
| US-20240067665-A1 | SMALL MOLECULES FOR BORON NEUTRON CAPTURE THERAPY | NME2, BTD, BLVRB | PTPN1 3566/4885ACE 4079/4885ITGB3 3125/4885 |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | PTPN1 3710/4885ACE 4363/4885ITGB3 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.